pfizerbrussels

Fake press release on drug pricing “erroneously attributed” to Pfizer

pharmafile | April 1, 2016 | News story | Medical Communications Pfizer, fake, false, legal action, press release, washington post 

Pfizer (NYSE: PFE) has issued a statement on a false press release related to drug pricing that was reported on by the Washington Post.

The Washington Post quickly took down the story but left an explanation as to the process involved in its original publication. They indicate that the press release was circulated from what appeared to a real Pfizer spokesperson. The domain of the web address, which has since been taken then, was a fake website that closely mirrored the real Pfizer website. A reporter from the Post called the phone number at the bottom of the press released and left a voicemail.

The genuine Pfizer statement reads: “A false press release related to drug pricing and linking to a fake web site was anonymously issued earlier today. It was erroneously attributed to Pfizer and should be disregarded. Pfizer is investigating this matter and evaluating its legal options against the parties responsible. Pfizer is committed to engaging in a honest discussion and real dialogue about the issues that matter to patients.”

Advertisement

Sean Murray

Related Content

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …

New Real-World Data Published in Journal of Cardiac Failure on Effectiveness

Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …

The Gateway to Local Adoption Series

Latest content